Document Detail

Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study.
MedLine Citation:
PMID:  18326619     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Galactooligosaccharides are selectively fermented by the beneficial member of the colonic microflora contributing to the health of the host. OBJECTIVE: We assessed the prebiotic potential of a novel galactooligosaccharide produced through the action of beta-galactosidases, originating from a probiotic Bifidobacterium bifidum strain, against a galactooligosaccharide produced through the action of an industrial beta-galactosidase and a placebo. DESIGN: Fifty-nine healthy human volunteers participated in this study. Initially, the effect of the matrix on the prebiotic properties of a commercially available galactooligosaccharide (7 g/d) was assessed during 7-d treatment periods with a 7-d washout period in between. During the second phase, 30 volunteers were assigned to a sequence of treatments (7 d) differing in the amount of the novel galactooligosaccharide (0, 3.6, or 7 g/d). Stools were recovered before and after each intervention, and bacteria numbers were determined by fluorescent in situ hybridization. RESULTS: Addition of the novel galactooligosaccharide mixture significantly increased the bifidobacterial population ratio compared with the placebo (P < 0.05), whereas 7 g/d of the novel galactooligosaccharide significantly increased the bifidobacterial ratio compared with the commercial galactooligosaccharide (P < 0.05). Moreover, a significant relation (P < 0.001) between the bifidobacteria proportion and the novel galactooligosaccharide dose (0, 3.6, and 7 g/d) was observed. This relation was similar to the effect of the novel galactooligosaccharide on the prebiotic index of each dose. CONCLUSIONS: This study showed that galactooligosaccharide mixtures produced with different beta-galactosidases show different prebiotic properties and that, by using enzymes originating from bifidobacterial species, an increase in the bifidogenic properties of the prebiotic product is achievable.
Flore Depeint; George Tzortzis; Jelena Vulevic; Kerry I'anson; Glenn R Gibson
Related Documents :
19835759 - Predicting mycotoxins in foods: a review.
24058809 - Jak-stat and feeding.
16864139 - Non-digestible oligosaccharides with prebiotic properties.
25255749 - Fermented broth in tyrosinase- and melanogenesis inhibition.
13933509 - Changes in the microflora of haddock fillets and shucked soft-shelled clams after irrad...
12691259 - Prebiotics and calcium bioavailability.
19926929 - Decrease of food intake in rats after ingestion of medium-chain triacylglycerol.
16302789 - Fumonisin mycotoxins in traditional xhosa maize beer in south africa.
19878279 - Food-anticipatory circadian rhythms: concepts and methods.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of clinical nutrition     Volume:  87     ISSN:  1938-3207     ISO Abbreviation:  Am. J. Clin. Nutr.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-03-10     Completed Date:  2008-04-15     Revised Date:  2009-05-15    
Medline Journal Info:
Nlm Unique ID:  0376027     Medline TA:  Am J Clin Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  785-91     Citation Subset:  AIM; IM    
School of Food Biosciences, The University of Reading, Reading, United Kingdom, and the Institute of Food Research, Colney, Norwich, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bifidobacterium / enzymology*
Colon / metabolism,  microbiology
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Feces / microbiology
Galactose / biosynthesis,  metabolism*
In Situ Hybridization, Fluorescence / methods
Oligosaccharides / biosynthesis,  metabolism*
beta-Galactosidase / metabolism*
Reg. No./Substance:
0/Oligosaccharides; 26566-61-0/Galactose; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans.
Next Document:  Organization of the core structure of the postsynaptic density.